Platelet rich plasma in ocular surface

Riestra, Ana Cristina; Alonso-Herreros, José María; Merayo‐Lloves, Jesús

doi:10.1016/j.oftale.2016.06.003

Cited by 7 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the last thirty years, there has been a special interest in developing drugs that mimic the characteristics of natural tears such as the regenerative, lubrication, antimicrobial and anti-inflammatory properties. Interestingly, the composition of blood plasma is very similar to tears in terms of osmolarity, pH and many proteins related to tissue regeneration [9][10][11]. In this sense, different blood-derived products like autologous serum (AS) and platelet-rich plasma (PRP) have been developed for the treatment of diverse ocular pathologies like dry eye disease, persistent epithelial defects, or corneal ulcers with satisfactory results [12].…”

Section: Introductionmentioning

confidence: 99%

Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum

Anitua

Muruzábal

Pino

et al. 2021

IJMS

View full text Add to dashboard Cite

Over the last three decades, there has been special interest in developing drugs that mimic the characteristics of natural tears for use it in the treatment of several ocular surface disorders. Interestingly, the composition of blood plasma is very similar to tears. Therefore, different blood-derived products like autologous serum (AS) and plasma rich in growth factors (PRGF) have been developed for the treatment of diverse ocular pathologies. However, scarce studies have been carried out to analyze the differences between both types of blood-derived products. In the present study, blood from three healthy donors was drawn and processed to obtain AS and PRGF eye drops. Then, human corneal stromal keratocytes (HK) were treated with PRGF or undiluted AS. Proteomic analysis was carried out to analyze and characterize the differential protein profiles between PRGF and AS, and the differentially expressed proteins in HK cells after PRGF and AS treatment. The results obtained in the present study show that undiluted AS induces the activation of different pathways related to an inflammatory, angiogenic, oxidative stress and scarring response in HK cells regarding PRGF. These results suggest that PRGF could be a better alternative than AS for the treatment of ocular surface disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum

Anitua

Muruzábal

Pino

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Various bloodderived products with different compositions, platelet concentrations, and leukocyte presence or absence can be obtained, including PDGF, plasma rich in growth factors (PRGF), PC, LR-PRP, LP-PRP, and more [53,54]. Over 40 preparation methods exist for PRGF, hindering comparisons of efficacy and safety in scientific studies [51,55]. Industrialized PRGF eye drops have shown preserved biological activity for 3 months in human use, benefiting severe dry eye patients unresponsive to conventional therapy, particularly in neutrophic cases.…”

Section: Platelet-rich Plasma (Prp)mentioning

confidence: 99%

“…Red and white blood cells can trigger undesirable inflammatory reactions. While leukocytes may have a negative pro-inflammatory effect, some studies indicate that non-platelet cellular components are crucial for optimal platelet function, including coagulation, growth factor release, and serum's ability to stimulate cell proliferation [53,55].…”

Section: Platelet-rich Plasma (Prp)mentioning

confidence: 99%

Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review

Bhujel,

Oh,

Kim

et al. 2023

Bioengineering

View full text Add to dashboard Cite

Dry eye disease (DED) is an emerging health issue affecting millions of individuals annually. Ocular surface disorders, such as DED, are characterized by inflammation triggered by various factors. This condition can lead to tear deficiencies, resulting in the desiccation of the ocular surface, corneal ulceration/perforation, increased susceptibility to infections, and a higher risk of severe visual impairment and blindness. Currently, the clinical management of DED primarily relies on supportive and palliative measures, including the frequent and lifelong use of different lubricating agents. While some advancements like punctal plugs, non-steroidal anti-inflammatory drugs, and salivary gland autografts have been attempted, they have shown limited effectiveness. Recently, there have been promising developments in the treatment of DED, including biomaterials such as nano-systems, hydrogels, and contact lenses for drug delivery, cell-based therapies, biological approaches, and tissue-based regenerative therapy. This article specifically explores the different strategies reported so far for treating DED. The aim is to discuss their potential as long-term cures for DED while also considering the factors that limit their feasibility and effectiveness. These advancements offer hope for more effective and sustainable treatment options in the future.

show abstract

“…Using these products combined with autologous and allogeneic bone grafts provides better grafting results than autogeneous bone alone (35)(36)(37). The main uses of PRP in ophthalmology are dry eye, graft-versus-host disease, persistent epithelial defects, corneal ulcers or perforations, burns and post-LASIK syndrome (27,(48)(49)(50). The regenerative potential of platelet-rich products has also been tested in tympanic perforation (51,52), skin lesions (53) -such as skin ulcers of multifactorial etiology: diabetic foot (54-56), pressure ulcers (57,58), venous ulcers (59) and even leprosy ulcers (60)-, vitiligo (61) and androgenetic alopecia (62).…”

Section: Clinical Uses Of Platelet-derived Bio-products and Concerns:mentioning

confidence: 99%

Platelet-derived bio-products: Classification update, applications, concerns and new perspectives

Acebes-Huerta

Arias-Fernández

Bernardo

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Platelet derived bio-products in the form of platelet rich plasma, plasma rich in growth factors, or plasma-free platelet releasates, are being studied worldwide with the aim of proving their efficacy in tissue regeneration within many different clinical areas, such as traumatology, maxillofacial surgery, ophthalmology, dermatology and otorhinolaryngology, amongst others. The current lack of consensus in the preparation method and application form, or in the quality assessment of each bio-product, precludes adequate interpretation of the relevance of reported clinical outcomes, and while many clinicians are very positive about them, as many are sceptic. Relevant aspects of these products are considered to propose a classification nomenclature, which would aid at the comprehensive comparison of clinical outcomes of bio-products of the same characteristics. Finally, the uses of platelet-derived bio-products in in vitro culture (for cell therapy purposes) as a substitute of animal-origin sera, and other future perspectives of applications of platelet-derived bio-products are discussed.

show abstract

Platelet rich plasma in ocular surface

Cited by 7 publications

References 54 publications

Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum

Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum

Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review

Platelet-derived bio-products: Classification update, applications, concerns and new perspectives

Contact Info

Product

Resources

About